Lund: Scientist/Senior Scientist Gene Therapy

Hitta ansökningsinfo om jobbet Scientist/Senior Scientist Gene Therapy i Lund. Är det intressant kan du gå vidare och ansöka jobbet. Annars kan du klicka på arbetsgivaren eller yrkesbenämningen för att se alla jobb i Lund inom den kategorin.

Publicerad: 2024-04-17 // Varaktighet: Heltid

Asgard Therapeutics is a spin-off from Lund University, Sweden, aiming to advance cancer immunotherapies by harnessing direct cell fate reprogramming technologies. Our lead program, AT-108, is a adenovirus-based gene therapy that reprograms cancer cells into antigen-presenting dendritic cells, unleashing the immune system against cancer. Asgard is expanding its multidisciplinary team that understands the value and opportunities of working in a startup based in a unique platform technology. We are looking for candidate who are creative and passionate about making a contribution to the cancer immunotherapy field and improve patients’ lives.
Position overview
We are seeking a highly enthusiastic and innovative Scientist/Senior Scientist searching for an opportunity to help building an early-stage company and contribute to the development of next generation cancer immunotherapies.
The successful candidate should have the ability to design experiments autonomously, analyze complex data, troubleshoot technical issues, and supervise junior staff. Strong interpersonal, verbal and written communication skills are required. Experimental rigor, scientific curiosity and ability to work in a fast-paced environment, adapting to evolving priorities are musts. The position will be lab-based and research activities will be performed in collaboration with the Cell Reprogramming in Hematopoiesis and Immunity Lab at Lund University (www.pereiralab.com).
Profile
Scientist/Senior Scientist with background in gene therapy vector development and validation to help developing AT-108. The candidate will develop and test adenoviral delivery systems to deliver reprogramming factors and explore potential optimization of the vector. The ideal candidate should have a proven track record in developing gene therapies, preferentially applied in vivo or in situ, as well as a broad understanding of viral-based immunotherapies and their applications to cancer treatment.
Responsibilities
Drive innovative research on in vivo direct reprogramming modalities, with particular focus on dendritic cell reprogramming and tumor targeting.
Design and generate novel adenoviral vectors that encode reprogramming factors.
Optimize sequences, tropism, and production of delivery system for enhanced efficacy and safety.
Develop functional and analytical methods to characterize the AT-108 gene therapy product.
Design, plan, and execute scientific experiments autonomously to complete program and company goals within designated timelines.
Collect and document primary data to maintain up to date records.
Analyze, summarize data in reports and communicate outputs to Asgard’s R&D and executive leadership team.

Qualifications:
PhD in molecular or cellular biology, genetics, biochemistry or related discipline, with 0-5 years of post-graduation experience in academic or industrial environment. Applicants within 2-years after completing their PhD studies are encouraged to apply.
In-depth expertise in development of viral gene therapy vectors, molecular cloning and vector production. Experience with adenoviral vectors is a plus.
Experience with general in vitro cell culture techniques, including culture of cell lines and primary cells.
Experience in multi-color flow cytometry analysis.
Previous experience in in vivo/in situ gene therapy is desirable. Experience in cell reprogramming is a plus.

Literature:
Zimmermannova O, Ferreira A, Ascic E, Santiago M, Kurochkin I, Hansen M, Met Ö, Inês Caiado I, Shapiro I, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério- Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa F, Pires C, Bassani-Sternberg M, Svane I, Pereira CF. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023).
Rosa FF, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannová O, Ferreira AG, Li H, Karlsson S, Scheding S, Pereira CF. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Sci Immunol. 2022 Mar 4;7(69):eabg5539.
Zimmermannova O, Caiado I, Ferreira AG and Pereira C-F (2021) Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Immunol. 12:714822. doi: 10.3389/fimmu.2021.714822
Pires CF, Rosa FF, Kurochkin I and Pereira C-F (2019) Understanding and Modulating Immunity With Cell Reprogramming. Front. Immunol. 10:2809. doi:10.3389/fimmu.2019.02809.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF. Direct Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells. Science Immunology 2018, 7, 3 (30).

Application:
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Asgard Therapeutics AB

Alla platsannonser →

Andra jobb i Lund som

Hittar inga andra jobb som i Lund.

Andra jobb i Lund från Asgard Therapeutics AB

Nedan visas andra jobb i Lund från Asgard Therapeutics AB .

Scientist/Senior Scientist In vivo Immuno-Oncology

Asgard Therapeutics AB
Immunolog
Läs mer Sep 3
About Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, backed by Johnson & Johnson Innovation – JJDC, Inc., RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden. Our lead candidate, AT-108, is a first-in-class gene therapy that reprograms tumor cells into antigen-presenting dendritic cells (cDC1), triggering a personalized and potent anti-tumor immune response.

Position Overview
The ideal in vivo scientist candidate will have a background in immuno-oncology and hands-on experience in in vivo research. The role will involve executing in vivo and in vitro experiments, analyzing data, troubleshooting technical issues, and contributing to ongoing projects. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and the ability to work in a fast-paced environment, adapting to evolving priorities, are musts.

Key responsibilities
Conduct in vivo studies using syngeneic and CDX mouse models to evaluate biodistribution, therapeutic efficacy, and safety.
Perform immunological assays including flow cytometry, ELISpot, T-cell co-culture assays, and cytokine profiling.
Analyze and summarize data in reports and communicate findings to Asgard's R&D and executive leadership team.
Assist in experiment planning, execution, and documentation according to standard protocols.


Qualifications
PhD degree in Immunology, Cancer Biology, Biomedicine, or a related life science discipline.
Hands-on experience with in vivo mouse work in an academic or industry setting.
Basic understanding of cancer immunotherapies is critical, knowledge of dendritic cell and T cell biology is a plus.
Experience in tumor biology-related in vitro assays, including multi-color flow cytometry for ELISpot and T-cell cytotoxicity assays.
Experience with small molecule and viral vectors handling and their in vivo administration is a plus.
Felasa B or equivalent animal handling certification is required.
Strong organizational skills and ability to work in a team-oriented environment.
Good written and verbal communication skills in English.


Literature
Ascic E, at al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024). DOI:10.1126/science.adn9083
Zimmermannova O, et al. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023). DOI: 10.1126/sciimmunol.add4817


Application
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu

Scientist/Senior Scientist In vitro Immuno-Oncology

Asgard Therapeutics AB
Immunolog
Läs mer Sep 3
About Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, backed by Johnson & Johnson Innovation – JJDC, Inc., RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden. Our lead candidate, AT-108, is a first-in-class gene therapy that reprograms tumor cells into antigen-presenting dendritic cells (cDC1), triggering a personalized and potent anti-tumor immune response.

Position Overview
The ideal in vitro scientist candidate will have a background in immuno-oncology and hands-on experience in in vitro research. The role will involve executing in vitro experiments, analyzing data, troubleshooting technical issues, and contributing to ongoing projects. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and the ability to work in a fast-paced environment, adapting to evolving priorities, are musts.

Key responsibilities
Conduct in vitro experiments using cell lines and primary samples, including monolayer cultures, spheroids, organoids, and tumoroids, to assess reprogramming efficiency.
Establish and optimize new models and methods to characterize immune responses, and troubleshoot technical issues.
Perform immunological assays including flow cytometry, ELISpot, T-cell co-culture assays, and cytokine profiling.
Analyze and summarize data in reports and communicate findings to Asgard's R&D and executive leadership team.
Assist in experiment planning, execution, and documentation according to standard protocols.


Qualifications
PhD degree in Immunology, Cancer Biology, Biomedicine, or a related life science discipline.
Extensive experience with general in vitro 2D and 3D cell culture techniques, including handling and processing primary tissue samples.
Basic understanding of cancer immunotherapies is critical, knowledge of dendritic cell and T cell biology is a plus.
Experience in tumor biology-related in vitro assays, including multi-color flow cytometry for ELISpot and T-cell cytotoxicity assays.
Experience with small molecule and viral vectors handling is a plus.
Felasa B or equivalent animal handling certification and in vivo experience is a plus.
Strong organizational skills and ability to work in a team-oriented environment.
Good written and verbal communication skills in English.


Literature
Ascic E, at al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024). DOI:10.1126/science.adn9083
Zimmermannova O, et al. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023). DOI: 10.1126/sciimmunol.add4817


Application
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu

Senior Scientist Immuno-oncology and Pipeline Development

Asgard Therapeutics AB
Forskare, cell- och molekylärbiologi
Läs mer Jul 30
About Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, backed by Johnson & Johnson Innovation – JJDC, Inc., RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden. Our lead candidate, AT-108, is a first-in-class gene therapy that reprograms tumor cells into antigen-presenting dendritic cells (cDC1), triggering a personalized and potent anti-tumor immune response.
Position overview
The ideal Senior Scientist Immuno-oncology and Pipeline Development candidate will have a background with expertise in in vivo research and non-viral-based delivery studies. The role will involve executing in vitro and in vivo experiments to support the development of the lead and pipeline programs. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and the ability to work in a fast-paced environment, adapting to evolving priorities, are a must.
Key responsibilities
Design, plan, and perform in vitro and in vivo experiments to support the development of Asgard’s lead and pipeline programs.
Establish, optimize, and document relevant methods, protocols, and SOPs to support experimental activities.
Serve as internal point of contact for interactions with CDMOs, consultants, and potential collaborators.
Collect, analyze, and document experimental data in a timely and accurate manner.
Communicate results and strategic insights effectively to the R&D and executive leadership team.
Train, mentor, and supervise junior team members as required.

Qualifications:
PhD degree in Immunology, Cancer Biology, Biomedicine, or a related life science discipline.
Hands-on experience with in vivo mouse work in an academic or industry setting.
Basic understanding of cancer immunotherapies is critical, knowledge of dendritic cell and T cell biology is a plus.
Experience in tumor biology-related in vitro assays, including multi-color flow cytometry for ELISpot and T-cell cytotoxicity assays.
Experience in RNA biology and development of RNA-based gene therapy vectors, molecular cloning, vector production, encapsulation in nanoparticles, and in vivo delivery is a plus.
Felasa B or equivalent animal handling certification is required.
Strong organizational skills and ability to work in a team-oriented environment.
Good written and verbal communication skills in English.

Literature
Ascic E, at al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024). DOI:10.1126/science.adn9083
Zimmermannova O, et al. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023). DOI: 10.1126/sciimmunol.add4817

Application:
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu

Scientist/Senior Scientist In vivo Immuno-Oncology

Asgard Therapeutics AB
Molekylärbiolog
Läs mer Nov 19
Asgard Therapeutics AB, Lund, Sweden
Asgard Therapeutics is a spin-off from Lund University, Sweden, aiming to advance cancer immunotherapies by harnessing direct cell fate reprogramming technologies. Our lead program, AT-108, is a adenovirus-based gene therapy that reprograms cancer cells into antigen-presenting conventional type 1 dendritic cells (cDC1s), unleashing the immune system against cancer. Asgard is expanding its multidisciplinary team that understands the value and opportunities of working in a startup based in a unique platform technology. We are looking for candidates who are creative and passionate about making a contribution to the cancer immunotherapy field and improve patients’ lives.
Position Overview
We are seeking a highly enthusiastic and innovative Scientist/Senior Scientist searching for an opportunity to help building an early-stage company and contribute to the development of next generation cancer immunotherapies.
The successful candidate should have the ability to design experiments autonomously, analyze complex data, troubleshoot technical issues, and supervise junior staff. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and ability to work in a fast-paced environment, adapting to evolving priorities are musts. The position will be lab-based and research activities will be performed in collaboration with the Cell Reprogramming in Hematopoiesis and Immunity Lab at Lund University (www.pereiralab.com) in the context of the EIC Pathfinder project ” RESYNC– Functional chemical reprogramming of cancer cells to induce antitumor immunity“. The RESYNC project aims to use small molecules to reprogram cancer cells into cDC1s in vivo after systemic administration of tumor-targeted nanoparticles.
Profile
Scientist/Senior Scientist with background in tumor immunology to work in the experimental validation of in vivo cDC1 reprogramming induced by AT-108 together with cDC1-promoting small molecules and exclusively mediated by small molecules. The candidate will focus on both efficacy and safety studies in syngeneic and CDX mouse models. The ideal candidate should have a Ph.D. degree in an immunology-related field with relevant in vitro and in vivo laboratory experience in academia or biotech industry.
Responsibilities
Evaluate efficacy of AT-108 in combination with small molecules, or cocktails of cDC1-inducing small molecules in animal models.
Develop methods to characterize the immune response induced by in vivo cDC1 reprogramming, including multi-color flow cytometry, fluorescence-activated cell sorting, T cell co-culture systems, MHC/peptide tetramer analysis, ELISpot, among other immunoassays.
Manage the RESYNC project from Asgard’s side, ensuring that resources are efficiently allocated. Design, plan, and execute scientific experiments autonomously in line with the Company/RESYNC Project goals within designated timelines.
Collect and document primary data to maintain up to date records, including electronic notebook and project reports.
Analyze, summarize data in reports and communicate data to Asgard’s R&D and executive leadership team.

Qualifications
PhD in Immunology, Cancer Biology, Biology or related field, with 0-5 years of post-graduation experience in academic or industrial environment.
Demonstrated knowledge of cancer immunotherapies, including experience in developing relevant in vivo immuno-oncology models (syngeneic and CDX tumor models) to understand mechanism of action underlying preclinical efficacy of cancer therapies.
Preferred qualifications include a background in dendritic cell biology and expertise in antigen presentation mechanisms, with a favorable consideration for candidates with knowledge in T cell biology.
Experience in the development and application of tumor biology-related in vitro assays, including multi-color flow cytometry for immune profiling, MHC/peptide tetramer, ELISpot and T-cell cytotoxicity assays. Experience with TCR sequencing and MHC peptidomics is a plus.
Experience with small molecule handling and their in vivo administration is a plus.
Felasa B certification.

Literature
Ascic E, Åkerström F, Nair MS, Rosa A, Kurochkin I, Zimmermannova O, Catena X, Rotankova N, Veser C, Rudnik M, Ballocci T, Schärer T, Huang X, Torres MR, Renaud E, Santiago VM, Met Ö, Askmyr D, Lindstedt M, Greiff L, Ligeon LA, Agarkova I, Svane I, Pires C, Rosa F, Pereira CF. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024). DOI:10.1126/science.adn9083
Zimmermannova O, Ferreira A, Ascic E, Santiago M, Kurochkin I, Hansen M, Met Ö, Inês Caiado I, Shapiro I, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério- Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa F, Pires C, Bassani-Sternberg M, Svane I, Pereira CF. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023).
Rosa FF, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannová O, Ferreira AG, Li H, Karlsson S, Scheding S, Pereira CF. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Sci Immunol. 2022 Mar 4;7(69):eabg5539.
Zimmermannova O, Caiado I, Ferreira AG and Pereira C-F (2021) Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Immunol. 12:714822. doi: 10.3389/fimmu.2021.714822
Pires CF, Rosa FF, Kurochkin I and Pereira C-F (2019) Understanding and Modulating Immunity With Cell Reprogramming. Front. Immunol. 10:2809. doi:10.3389/fimmu.2019.02809.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF. Direct Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells. Science Immunology 2018, 7, 3 (30).

Application
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu

Scientist/Senior Scientist Organoid Immuno-Oncology

Asgard Therapeutics AB
Forskare, immunologi
Läs mer Apr 19
Asgard Therapeutics is a spin-off from Lund University, Sweden, aiming to advance cancer immunotherapies by harnessing direct cell fate reprogramming technologies. Our lead program, AT-108, is a adenovirus-based gene therapy that reprograms cancer cells into antigen-presenting dendritic cells, unleashing the immune system against cancer. Asgard is expanding its multidisciplinary team that understands the value and opportunities of working in a startup based in a unique platform technology. We are looking for candidate who are creative and passionate about making a contribution to the cancer immunotherapy field and improve patients’ lives.
Position overview
We are seeking a highly enthusiastic and innovative Scientist/Senior Scientist searching for an opportunity to help building an early-stage company and contribute to the development of next generation cancer immunotherapies.
The successful candidate should have the ability to design experiments autonomously, analyze complex data, troubleshoot technical issues, and supervise junior staff. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and ability to work in a fast-paced environment, adapting to evolving priorities are musts. The position will be lab-based and research activities will be performed in collaboration with the Cell Reprogramming in Hematopoiesis and Immunity Lab at Lund University (www.pereiralab.com).
Profile
Scientist/Senior Scientist with background in tumor immunology to work in the experimental validation of AT-108. The candidate will be responsible for establishing patient-derived monolayer and organoid/tumoroids 3D cell culture models to validate AT-108 efficacy ex vivo. The ideal candidate should have a Ph.D. degree in an immunology-related field with relevant laboratory experience in academia or biotech industry, including experience in mammalian cell culture including primary cell isolation and handling, as well as 3D co-culture systems.
Responsibilities
Establish patient-derived organoid models and perform detailed phenotyping using cutting-edge image analysis and flow cytometry analysis.
Troubleshoot technical difficulties encountered in primary spheroid/organoid/tumoroid establishment, growth (media and growth factors) and testing.
Establish methods to characterize the immune response induced by AT-108 ex vivo, including multi-color flow cytometry, fluorescence-activated cell sorting, T cell co-culture systems, among other immune assays.
Evaluate AT-108 ex-vivo efficacy in human monolayer and spheroid, organoid, and tumoroid models in terms of cDC1 reprogramming efficiency, as well as co-culture with relevant immune cell population to characterize induced immune response.
Design, plan, and execute scientific experiments autonomously to complete program and company goals within designated timelines.
Collect and document primary data to maintain up to date records.
Analyze, summarize data in reports and communicate outputs to Asgard’s R&D and executive leadership team.

Qualifications:
PhD in Immunology, Cancer Biology, Biology or related field, with 0-5 years of post- graduation experience in academic or industrial environment. Applicants within 2-years after completing their PhD studies are encouraged to apply.
Extensive experience with general in vitro 2D and 3D cell culture techniques, including handling and processing primary tissue samples.
Demonstrated knowledge of cancer immunotherapies, including experience in developing relevant ex-vivo immuno-oncology models (patient-derived organoids) to understand mechanism of action underlying preclinical efficacy of cancer therapies.
Experience in dendritic cell biology and antigen presentation mechanisms is ideal, T cell biology is also attractive.
Experience in the development and application of tumor biology-related in vitro assays, including multi-color flow cytometry for immune profiling, FACS, T-cell cytotoxicity assays, complex cell-based functional assays (such as antigen presentation and cancer cell cytotoxicity).
Experience in imaging-based approaches for 3D culture systems.

Literature:
Zimmermannova O, Ferreira A, Ascic E, Santiago M, Kurochkin I, Hansen M, Met Ö, Inês Caiado I, Shapiro I, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério- Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa F, Pires C, Bassani-Sternberg M, Svane I, Pereira CF. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023).
Rosa FF, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannová O, Ferreira AG, Li H, Karlsson S, Scheding S, Pereira CF. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Sci Immunol. 2022 Mar 4;7(69):eabg5539.
Zimmermannova O, Caiado I, Ferreira AG and Pereira C-F (2021) Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Immunol. 12:714822. doi: 10.3389/fimmu.2021.714822
Pires CF, Rosa FF, Kurochkin I and Pereira C-F (2019) Understanding and Modulating Immunity With Cell Reprogramming. Front. Immunol. 10:2809. doi:10.3389/fimmu.2019.02809.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF. Direct Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells. Science Immunology 2018, 7, 3 (30).

Application:
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu

Scientist/Senior Scientist In vivo Immuno-Oncology

Asgard Therapeutics AB
Forskare, immunologi
Läs mer Apr 19
Asgard Therapeutics is a spin-off from Lund University, Sweden, aiming to advance cancer immunotherapies by harnessing direct cell fate reprogramming technologies. Our lead program, AT-108, is a adenovirus-based gene therapy that reprograms cancer cells into antigen-presenting dendritic cells, unleashing the immune system against cancer. Asgard is expanding its multidisciplinary team that understands the value and opportunities of working in a startup based in a unique platform technology. We are looking for candidate who are creative and passionate about making a contribution to the cancer immunotherapy field and improve patients’ lives.
Position overview
We are seeking a highly enthusiastic and innovative Scientist/Senior Scientist searching for an opportunity to help building an early-stage company and contribute to the development of next generation cancer immunotherapies.
The successful candidate should have the ability to design experiments autonomously, analyze complex data, troubleshoot technical issues, and supervise junior staff. Strong interpersonal, verbal, and written communication skills are required. Experimental rigor, scientific curiosity, and ability to work in a fast-paced environment, adapting to evolving priorities are musts. The position will be lab-based and research activities will be performed in collaboration with the Cell Reprogramming in Hematopoiesis and Immunity Lab at Lund University (www.pereiralab.com).
Profile
Scientist/Senior Scientist with background in tumor immunology to work in the experimental validation of AT-108. The candidate will focus on both efficacy and safety studies in multiple syngeneic and CDX mouse models. The ideal candidate should have a Ph.D. degree in an immunology-related field with relevant in vitro and in vivo laboratory experience in academia or biotech industry.
Responsibilities
Evaluate efficacy of AT-108 in animal models.
Establish methods to characterize the immune response induced by in vivo cDC1 reprogramming, including multi-color flow cytometry, fluorescence-activated cell sorting, T cell co-culture systems, MHC/peptide tetramer analysis, ELISpot, among other immunoassays.
Design, plan, and execute scientific experiments autonomously to complete program and company goals within designated timelines.
Collect and document primary data to maintain up to date records.
Analyze, summarize data in reports and communicate data to Asgard’s R&D and executive leadership team.

Qualifications:
PhD in Immunology, Cancer Biology, Biology or related field, with 0-5 years of post-graduation experience in academic or industrial environment.
Demonstrated knowledge of cancer immunotherapies, including experience in developing relevant in vivo immuno-oncology models (syngeneic and CDX tumor models) to understand mechanism of action underlying preclinical efficacy of cancer therapies.
Preferred qualifications include a background in dendritic cell biology and expertise in antigen presentation mechanisms, with a favorable consideration for candidates with knowledge in T cell biology.
Experience in the development and application of tumor biology-related in vitro assays, including multi-color flow cytometry for immune profiling, MHC/peptide tetramer, ELISpot and T-cell cytotoxicity assays. Experience with TCR sequencing and MHC peptidomics is a plus.
Felasa B certification.

Literature:
Zimmermannova O, Ferreira A, Ascic E, Santiago M, Kurochkin I, Hansen M, Met Ö, Inês Caiado I, Shapiro I, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério- Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa F, Pires C, Bassani-Sternberg M, Svane I, Pereira CF. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. Science Immunology 8, eadd4817 (2023).
Rosa FF, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannová O, Ferreira AG, Li H, Karlsson S, Scheding S, Pereira CF. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Sci Immunol. 2022 Mar 4;7(69):eabg5539.
Zimmermannova O, Caiado I, Ferreira AG and Pereira C-F (2021) Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Immunol. 12:714822. doi: 10.3389/fimmu.2021.714822
Pires CF, Rosa FF, Kurochkin I and Pereira C-F (2019) Understanding and Modulating Immunity With Cell Reprogramming. Front. Immunol. 10:2809. doi:10.3389/fimmu.2019.02809.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF. Direct Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells. Science Immunology 2018, 7, 3 (30).

Application:
Please email your CV, cover letter and contact information for two references to careers@asgardthx.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.

Ansök nu
Copyright © 2025 - Alla rättigheter reserverade.